Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
Rojas M, Rodríguez Y, Hernández JC, Díaz-Coronado JC, Vergara JAD, Vélez VP, Mancilla JP, Araujo I, Yepes JT, Ricaurte OB, Pardo-Oviedo JM, Monsalve DM, Acosta-Ampudia Y, Ramírez-Santana C, García PG, Landinez LA, Correales LD, Grass JS, Pérez CR, López GS, Mateus N, Mancera L, Devia RR, Orjuela JE, Parra-Moreno CR, Buitrago AA, Ordoñez IE, Osorio CF, Ballesteros N, Patiño LH, Castañeda S, Muñoz M, Ramírez JD, Bastard P, Gervais A, Bizien L, Casanova JL, Camacho B, Gallo JE, Gómez O, Rojas-Villarraga A, Pérez CE, Manrique R, Mantilla RD, Anaya JM.
Rojas M, et al. Among authors: pardo oviedo jm.
BMC Infect Dis. 2022 Jun 27;22(1):575. doi: 10.1186/s12879-022-07560-7.
BMC Infect Dis. 2022.
PMID: 35761219
Free PMC article.
Clinical Trial.